Dear AuntMinnie Member,
The market for diagnostic radiopharmaceuticals is poised for growth in the coming years, thanks to a new wave of radiotracers approaching the market.
This new generation should prove more successful than the previous wave of products, which largely failed to prompt significant growth in radiopharmaceutical sales due to their relatively narrow range of indications, according to a new article in our Molecular Imaging Digital Community by market research firm Bio-Tech Systems of Las Vegas.
The new radiopharmaceuticals have much broader applicability, and are targeting workhorse molecular imaging procedures in areas such as cardiology, as well as cutting-edge applications like infection and inflammation. The broader imaging platforms will be more likely to spur clinicians to invest the time and resources necessary to learn how to use the new products, the article predicts.
Learn about specific new radiopharmaceuticals and how they may impact your practice in years to come by clicking here.
When you're done, we invite you to read about a new advisory by the SNM (formerly the Society of Nuclear Medicine). The article offers travel tips for nuclear medicine patients with residual radiation who may be experiencing travel delays due to enhanced security screening procedures. Find out what to tell your patients by clicking here.
